Introduction: Multiple Myeloma is an incurable blood cancer, with few patients surviving more than 10 years post-diagnosis. Autologous stem cell transplants have been shown to lengthen progression-free survival after diagnosis, with a median of 13.8 years. An autologous stem cell transplant uses healthy hematopoietic stem cells from a person’s own body, which are later, after high-dose chemotherapy, given back to repair damaged or diseased bone marrow.

Case Description: This case follows a 70-year-old male with a history of Multiple Myeloma. Post-diagnosis of MM in remission, the patient underwent an autologous stem cell transplant. Six months later, he received six required vaccinations at once, then a second dose of four two-dose vaccinations, and is current on all vaccinations required for children/adults nearly a year post-ASCT.

Discussion: A tailored immune support protocol is crucial after autologous stem cell transplants for Multiple Myeloma. The timely use of immunotherapy, prophylaxis, and full vaccine re-administration significantly reduces infection risk, supporting immune recovery, preventing complications, and enhancing long-term quality of life in patients with Multiple Myeloma. The treatments administered to this patient support a strengthened immune system and align with national immunization guidelines. At 11 months post-transplant, the patient remains in remission, with no infections or hospitalizations, and a return to full daily activities. He continues to be monitored and is thriving as a long-term responder.